0.02Open0.02Pre Close0 Volume638 Open Interest2.00Strike Price0.00Turnover0.00%IV66.94%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma60.50Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Cue Biopharma Stock Discussion
Pharmaceutical: $Esperion Therapeutics (ESPR.US)$ $Seelos Therapeutics (SEEL.US)$ $Scilex Holding (SCLX.US)$ $Trevena (TRVN.US)$ $111 Inc (YI.US)$ $Cue Biopharma (CUE.US)$
Frac Sand: $Smart Sand (SND.US)$
Graphite Electrode: $GrafTech (EAF.US)$
Crypto Mining: $Bit Origin (BTOG.US)$
Artificial Intelligence: $Veritone (VERI.US)$
IOT Security: $Gorilla Technology (GRRR.US)$
Holographic: $WiMi Hologram Cloud (WIMI.US)$
Real Est...
📊⚡️📊
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
Cue Biopharma (Nasdaq: CUE) announced two presentations at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024) in Houston, Texas, from November 6-10, 2024. The presentations will focus on their clinical assets CUE-101 and CUE-102, part of the CUE-100 series.
An oral presentation by Dr. Christine Chung will discuss a ph...
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
Cue Biopharma has presented updated data from its Phase 1 trial of CUE-101 at the 2024 ASCO Annual Meeting, revealing promising results for HPV+ head and neck cancer. The combination of CUE-101 and pembrolizumab in first-line (1L) treatment showed a 46% overall response rate (ORR) and a 96% 12-month overall survival (OS). ...
NEED IT TO BREAK OVER: $15.40
key indicator for MORE uptrend $15.55
confirmation uptrend - $16.16
mini breakout - $16.37
full breakout - $17.31
SEMI PARABOLIC - $18.25
stop loss - $14.31
support - $12.98. $Cue Biopharma (CUE.US)$
No comment yet